Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
Department of Pathology, Faculty of Medicine, University of Kordofan, El-Obeid, Sudan.
PLoS One. 2023 Apr 17;18(4):e0284223. doi: 10.1371/journal.pone.0284223. eCollection 2023.
Vancomycin has been widely used in the last six decades to treat methicillin-resistant S. aureus (MRSA) and other resistant gram-positive infections. The risk of vancomycin toxicity increases with the utilization of higher doses while treating the resistant form of bacterial infections. Nephrotoxicity is one of the major complications reported to be a hinderance in the prognosis of vancomycin therapy.
This hospital-based study aimed to highlight the influence of vancomycin on renal function with special emphasis on identifying the predictors and augmenting factors for nephrotoxicity.
A cross-sectional, unicentric, hospital-based study was conducted at King Fahad Specialist Hospital (KFSH) in Qassim region in Saudi Arabia (KSA). It included 319 hospitalized patients who received vancomycin at intermittent doses (15 to 30 mg/kg IV per day) based on the diseased state. Data regarding vancomycin dose, frequency, duration and data of renal function tests and type of admission were analysed to evaluate their influence on the renal function using parameters such as blood urea, serum creatinine levels and creatinine clearance. One-way ANOVA and Spearman correlation test were used in the analysis of data.
Both male and female patients treated with vancomycin had significantly (p<0.05) elevated blood urea and serum creatinine levels compared to baseline levels while creatinine clearance was non-significantly varied. Increasing age, increasing body weight, higher vancomycin dose and trough levels, increased vancomycin frequency and duration, critically ill patients and site of infection were factors associated with significant (p<0.05) increases in blood urea and serum creatinine levels with reduction in creatinine clearance.
Data suggested that vancomycin treatment reduced the renal function in patients and indicated its association with several predictors and confounding factors. The findings of the study might assist in identifying the patients under risk from the vancomycin-induced nephrotoxicity and in designing the preventive strategies to reduce such complications.
在过去的六十年中,万古霉素被广泛用于治疗耐甲氧西林金黄色葡萄球菌(MRSA)和其他耐药革兰氏阳性感染。在治疗耐药形式的细菌感染时,使用更高剂量会增加万古霉素毒性的风险。肾毒性是报告的主要并发症之一,会阻碍万古霉素治疗的预后。
本基于医院的研究旨在强调万古霉素对肾功能的影响,特别强调确定肾毒性的预测因子和增强因素。
在沙特阿拉伯(KSA)卡西姆地区的法赫德国王专科医院(KFSH)进行了一项横断面、单中心、基于医院的研究。它包括 319 名接受间歇性剂量(15 至 30 毫克/公斤静脉注射/天)万古霉素治疗的住院患者,具体剂量取决于病情。分析了万古霉素剂量、频率、持续时间以及肾功能检查和入院类型的数据,以使用血尿素、血清肌酐水平和肌酐清除率等参数评估其对肾功能的影响。在分析数据时使用了单向方差分析和斯皮尔曼相关检验。
接受万古霉素治疗的男性和女性患者的血尿素和血清肌酐水平均明显(p<0.05)高于基线水平,而肌酐清除率无明显变化。年龄增长、体重增加、万古霉素剂量和谷值升高、万古霉素频率和持续时间增加、危重症患者和感染部位是与血尿素和血清肌酐水平升高(p<0.05)相关的因素,与肌酐清除率降低相关。
数据表明,万古霉素治疗降低了患者的肾功能,并表明其与几个预测因子和混杂因素有关。该研究的结果可能有助于识别有万古霉素引起的肾毒性风险的患者,并设计预防策略以减少此类并发症。